Related Experiment Video
Updated: Aug 7, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
P53 mutants suppress ZBP-89 function
Morihiro Okada1, Arthur Tessier, Longchuan Bai
1Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-2200, USA.
Background:
ZBP-89 is a widely expressed Krüppel-type zinc finger transcription factor that binds to GC-rich elements and represses or activates known target genes. ZBP-89 stabilizes wild-type p53 and can induce apoptosis independently of p53. Tissues with p53 mutations are predisposed to transformation and are more resistant to chemotherapy.
Materials And Methods:
The effect of ZBP-89 on seven sporadic p53 mutants was investigated. It was then examined whether a cell null for p53 in comparison to one expressing mutated p53 is more sensitive or resistant to chemotherapy in the presence of increased levels of ZBP-89.
Results:
None of the p53 mutations were stabilized by ZBP-89 except for the A161T p53 mutation, which exhibited constitutive transcriptional activity. ZBP-89 potentiated p53-mediated cell death with 10 nM staurosporine and 100 nM etoposide, but did not in the presence of the R273H p53 mutation.
Conclusion:
ZBP-89 is an important co-activator of wild-type p53 and both proteins are negatively affected by functionally inactive p53 mutants.
Insights
Zinc finger protein ZBP-89 acts as a co-activator for wild-type p53. Functionally inactive p53 mutants negatively impact ZBP-89 activity, affecting chemotherapy sensitivity.
Area of Science:
- Molecular Biology
- Cancer Research
- Transcription Factors
Background:
- ZBP-89 is a transcription factor that regulates gene expression and influences apoptosis.
- Wild-type p53 is a tumor suppressor, and its mutations are linked to cancer development and chemotherapy resistance.
Purpose of the Study:
- To investigate the interaction between ZBP-89 and various p53 mutants.
- To determine how ZBP-89 affects chemotherapy sensitivity in cells with wild-type, mutated, or absent p53.
Main Methods:
- Studied the effect of ZBP-89 on seven sporadic p53 mutants.
- Assessed chemotherapy sensitivity in p53-null versus p53-mutant cells with altered ZBP-89 levels.
Main Results:
- ZBP-89 stabilized wild-type p53 but only the A161T p53 mutation showed constitutive activity.
- ZBP-89 enhanced p53-mediated cell death with specific chemotherapeutic agents, except for the R273H p53 mutation.
- Chemotherapy sensitivity varied depending on p53 status and ZBP-89 levels.
Conclusions:
- ZBP-89 functions as a crucial co-activator for wild-type p53.
- Inactive p53 mutants can disrupt the ZBP-89/p53 pathway, impacting therapeutic outcomes.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
The Intrinsic Apoptotic Pathway

